|
 |
InfergenThis page contains recent news articles, when available, and an overview of Infergen but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The DIRECT trial is evaluating the daily use of Infergen in combination with ... Patients receiving Infergen 15 µg daily with a washout period less than the ... RedOrbit … of Clinical Data From Studies of Daily Infergen With and Without... - May 16, 2005 ..."We believe treatment with daily Infergen plus ribavirin may become a promising ... Patients were then retreated with daily Infergen (15 micrograms) plus ... RedOrbit Valeant sells rights to hepatitis C drug - Dec 20, 2007 Infergen, a 10-year-old form of interferon originally developed by Amgen Inc (AMGN.O), is approved for use by itself to treat adults with hepatitis C who ... Reuters Earnings Roundup; Valeant takes hit in quarter - Nov 2, 2007 Valeant said it planned to sell its Infergen operations and had recorded results ... Infergen accounted for sales of about $8.6 million and costs of about ... Pay-Per-View - Los Angeles Times - ProQuest Archiver Valeant Pharmaceuticals Initiates Infergen(R) Phase 4 Study - Dec 12, 2006 Valeant Pharmaceuticals International (NYSE:VRX) today announced its plans to initiate a phase 4 study of Infergen(R) (Consensus Interferon), ... Genetic Engineering News - Genetic Engineering News (press release) … signs license agreement with Amgen for commercialising of Infergen. - Sep 17, 2008 Three Rivers Pharmaceuticals will obtain commercial rights to Infergen in all ... Infergen is indicated for the treatment of chronic HCV infection in ... $9.94 - M2 Europharma - Alacra Store InterMune divesting Infergen for $135.5m.(Wednesday, Nov. 30) - Dec 5, 2005 Six months after selling its anti-infective drug Amphotec to Three Rivers Pharmaceuticals LLC, InterMune Inc. has agreed to dispense US and Canadian rights ... Free with registration - BioWorld Week - AccessMyLibrary.com … Pharmaceuticals Previews 24-Week Results of Direct Trial for Inferg... - Oct 2, 2006 The DIRECT trial is evaluating the daily use of Infergen in combination with ... Patients receiving Infergen 15 [acute accent]g daily with a washout period ... Free with registration - Business Wire - AccessMyLibrary.com … Completes Divestment of Hep-C Drug Infergen(R) to Three Rivers … - Jan 14, 2008 Infergen is a registered trademark of Amgen, Inc., and Three Rivers Pharmaceuticals, LLC is the exclusive licensee from Amgen of this mark for use in the ... Genetic Engineering News - Genetic Engineering News (press release) … Completes Acquisition of Hep-C Drug Infergen(R) From InterMune - Jan 3, 2006 Infergen or consensus interferon, is a bio-optimized, selective and highly ... Infergen is the only interferon with data in the label regarding use in ... RedOrbit Valeant Pharma sells Argentina commercial business - Jun 10, 2008 Valeant has also cut costs, selling off its hepatitis C drug Infergen and divesting subsidiaries and product rights in Asian countries in a deal that closed ... Boston Globe … Announces Presentation of Data on Infergen Plus Actimmune for the ... - May 16, 2005 InterMune Announces Presentation of Data on Infergen Plus Actimmune for the Treatment of HCV PEG-Nonresponders. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research InterMune completes divestiture of Infergen for up to $135.5 M in... - Jan 3, 2006 InterMune Inc announced the completion of the sale of its US and Canadian rights to Infergen (interferon alfacon-1), approved for the treatment of chronic ... Pay-Per-View - Company Reports - Factiva, from Dow Jones Ike wreaks havoc on Internet usage - Sep 18, 2008 ...said it signed a licensing agreement with Amgen Inc. to expand its marketing rights for the hepatitis C drug Infergen to all markets except Japan. Pittsburgh Post-Gazette - Pittsburgh Post Gazette Event Brief of Q3 2005 InterMune Inc. Earnings Conference Call - Part... - Oct 2, 2005 We also have on top of that a 31 person Infergen team that only does Infergen and since January of 2005 that mix has not changed at all. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Event Brief of Q4 2006 Valeant Pharmaceuticals International Earnings... - Feb 28, 2007 In addition to acquisition of Infergen and launch of Zelapar and Cesamet ... Infergen: 1. 2006 sales totaled $43m. 2. Demand weakened during year due to: 1. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Hepatitis C Virus; Data presented on Infergen plus Actimmune for … - Jun 20, 2005 2005 JUN 20 - (NewsRx.com) -- InterMune, Inc., (ITMN) announced the presentation of final data from a retrospective clinical analysis evaluating the ... Pay-Per-View - Gastroenterology Week - Factiva, from Dow Jones … Intl acquires InterMune Inc-Infergen rights from InterMune Inc -... - Jan 3, 2006 US - Valeant Pharmaceuticals International acquired the United States and Canadian rights to the hepatitis C drug Infergen of InterMune Inc, a developer of ... Pay-Per-View - deals - Alacra Store … Pharmaceuticals acquires Valeant Pharm Intl-Infergen(R) from... - Jan 14, 2008 Valeant Pharmaceuticals International (VRX) Product Name Infergen ... Valeant Pharmaceuticals International Infergen Hepatitis C Program Update Deals… ... Pay-Per-View - deals - Alacra Store INTERMUNE TO CUT JOBS, SELL OFF RIGHTS TO DRUG - Nov 29, 2005 ...plans to cut 160 jobs and agreed to sell the rights to its hepatitis C drug Infergen for as much as $136 million to finance research on other compounds. ... $2.95 - San Jose Mercury News - NewsBank Pharmaceuticals firm to double jobs, triple space - Dec 28, 2007 Infergen will continue to be made in California by Amgen, its original developer, ... Acquiring the rights to Infergen represents "a perfect fit" for Three ... pittsburghlive.com InterMune Announces Third Quarter Financial Results and Business … - Oct 27, 2005 Infergen(R) revenues for the third quarter of 2005 increased by 63% to $10.2 ... Sales of Infergen(R) for the first nine months of 2005 increased by 79% to ... Free with registration - PR Newswire - AccessMyLibrary.com Thursday's Worst Stocks in the World - Nov 2, 2007 Valeant says that Infergen cost it $18.6 million in Q3 but produced just $8.6 ... Translation: Infergen is the latest on a list of way too many misses ... fool.com Valeant Pharmaceuticals Reports 2006 Second Quarter Results; Product ... - Aug 3, 2006 Infergen was acquired at the end of last year and had sales of $11.3 million ... Excluding Infergen, product sales increased nine percent in the 2006 second ... Free with registration - Business Wire - AccessMyLibrary.com … (R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmace - Jan 14, 2008 ..."Adding Infergen to our growing portfolio is very exciting," said Donald J. Kerrish ... Infergen, or consensus interferon, is a bio-optimized, selective and ... Pay-Per-View - PR Newswire - HighBeam Research InterMune Inc. Conference Call - Part 1. - Nov 29, 2005 Namely, our broad and deep pipeline and our rapidly growing Infergen brand. ... These promising development programs and growing the Infergen brand each ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Q3 2006 Valeant Pharmaceuticals International Earnings Conference … - Nov 2, 2006 In addition, Infergen has particularly been impacted by a very tough ... Many key opinion leaders are convinced that Infergen has advantages over ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Infergen bought.(RXs)(Infergen bought by Three Rivers Pharmaceuticals... - Feb 4, 2008 Infergen bought.(RXs)(Infergen bought by Three Rivers Pharmaceuticals LLC from Valeant Pharmaceuticals International)(Brief article) ... find Chain Drug ... Pay-Per-View - Chain Drug Review - HighBeam Research InterMune Announces Second Quarter Financial Results. - Jul 28, 2005 Infergen(R) (interferon alfacon-1) sales for the second quarter of 2005 increased ... Sales of Infergen for the first six months of 2005 increased by 91% to ... $4.95 - PR Newswire - ECNext Press Release: InterMune Completes Divestiture of Infergen(R) for up... - Jan 3, 2006 InterMune Completes Divestiture of Infergen(R) for up to $135.5 Million in Cash. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Three Rivers finalizes acquisition of Infergen from Valeant. - Jan 21, 2008 Three Rivers finalizes acquisition of Infergen from Valeant. Three Rivers Pharmaceuticals has finalized its acquisition of the hepatitis C drug Infergen ... $9.94 - Pharma Marketletter - Alacra Store InterMune Announces Fourth Quarter and Year End 2005 Financial … - Feb 2, 2006 As a result of the December 30, 2005 divestiture of Infergen(R) and in compliance ... Including $3.9 million of discontinued cost of goods for Infergen(R), ... Free with registration - PR Newswire - AccessMyLibrary.com InterMune and Array expand Hep C collaboration - Jul 20, 2005 ..."In addition to our protease inhibitor program, we are advancing our late stage HCV pipeline in PEG-nonresponders and growing our marketed brand, Infergen ... DrugResearcher.com Infergen bought. - Feb 4, 2008 Three Rivers Pharmaceuticals LLC has acquired Infergen, a hepatitis C drug, from Valeant Pharmaceuticals International. The deal is valued at about $91 ... $9.94 - Chain Drug Review - Alacra Store InterMune Announces Clinical Data Presented at AASLD That Support … - Nov 14, 2005 ..."Infergen(R) is currently approved for the treatment of chronic HCV infection ... The authors concluded that these data suggest that daily Infergen(R) plus ... Free with registration - PR Newswire - AccessMyLibrary.com Making Headway Against Hepatitis C: New Drug Combo Effective in Non- … - Oct 31, 2006 They have shown that a cocktail of ribavirin and Infergen, a highly potent ... Fourteen percent of patients taking 9mcg of Infergen daily and 20 percent ... Infection Control Today Liver damage can be reversed - Oct 30, 2006 They have shown that a cocktail of ribavirin and Infergen, a highly potent ... Fourteen percent of patients taking 9mcg of Infergen daily and 20 percent ... News-Medical.net InterMune Announces Fourth Quarter and Year End Financial Results; - ... - Feb 7, 2005 This increase is largely attributable to the creation of a new Infergen sales ... Infergen revenue in 2004 totaled $22.3 million compared to $9.3 million in ... $4.95 - PR Newswire - ECNext … (R), LLC Obtains Additional Commercial Rights to Infergen(R) from Am - Sep 17, 2008 Three Rivers Pharmaceuticals(R), LLC Obtains Additional Commercial Rights to Infergen(R) from Amgen Inc. from PR Newswire Europe. Pay-Per-View - PR Newswire Europe - HighBeam Research Press Release: InterMune Announces Fourth Quarter and Year End 2005 … - Feb 2, 2006 As a result of the December 30, 2005 divestiture of Infergen(R) and in compliance ... Article: InterMune Relaunches Infergen for Hepatitis C Infections. ... Pay-Per-View - PR Newswire - HighBeam Research InterMune Announces Presentations on Actimmune and IPF at ATS 2005 - May 9, 2005 Leading the hepatology portfolio is the DIRECT Trial, a Phase III study of daily Infergen(R) (interferon alfacon-1) plus ribavirin, and a Phase IIb trial of ... RedOrbit Promising Results From Phase II Study of Pirfenidone in IPF Patients - May 2, 2005 Leading the hepatology portfolio is the DIRECT trial, a Phase III study of daily Infergen(R) (interferon alfacon-1) plus ribavirin, and a Phase IIb trial of ... RedOrbit Valeant出售丙è‚?è?¯ç‰©Infergen北美è?¯å“?æ?ƒåˆ© - Dec 20, 2007 ...ã€?MarketWatch纽约12月20日讯】总部ä½?äºŽåŠ å·žCosta Mesaçš„Valeant Pharmaceuticals International(VRX)周四宣布ç¾ç½²äº†ä¸€é¡¹æ£å¼?å??议，å?Œæ„?将丙è‚?è?¯ç‰©Infergen在美国和 ... 新浪网 Loislaw Federal District Court Opinions - EDMONDS v. REES (WDKy. 3- … - Mar 18, 2008 However, because those medications were not working, in March 2004, Dr. Cecil prescribed Infergen and Ribavirin. A May 20, 2004, letter from Dr. Cecil to ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw Valeant reports strong 48-week data for Infergen - Nov 1, 2006 The USA's Valeant Pharmaceuticals presented encouraging 48-week data from a trial of its hepatitis C drug Infergen (interferon alfacon 1). ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones … of Clinical Data From Studies of Daily Infergen With and Withou - May 16, 2005 A Second Study Provides Support for Daily Infergen vs. Three-Times-Per-Week Infergen -. CHICAGO, May 16 /PRNewswire-FirstCall/ -- InterMune, Inc. announced ... Pay-Per-View - PR Newswire - HighBeam Research Valeant to out-license programs in restructuring - Apr 3, 2006 Valeant will concentrate development efforts on Viramidine (taribavirin), retigabine and Infergen. The drug developer will also look to cut costs in sales ... FierceBiotech … of the Phase III DIRECT trial evaluating daily Infergen plus... - Jul 11, 2005 InterMune Inc announced the completion of patient enrolment in its Phase III clinical trial of daily Infergen (interferon alfacon-1) in combination with ... Pay-Per-View - Company Reports - Factiva, from Dow Jones InterMune Announces Webcast of Corporate Presentation at the … - Sep 8, 2005 In addition to three-times-a-week Infergen(R) (interferon alfacon-1), a currently marketed product indicated for the treatment of chronic hepatitis C virus ... Free with registration - PR Newswire - AccessMyLibrary.com … (R), LLC Obtains Additional Commercial Rights to Infergen(R) from Am - Sep 17, 2008 Three Rivers Pharmaceuticals(R), LLC Obtains Additional Commercial Rights to Infergen(R) from Amgen Inc. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research InterMune posts 2004 results.(pharmaceutical industry)(Brief Article) - Feb 21, 2005 Sales of Infergen were $8.2 million, an increase of 151%. As of December 31, 2004, the company's cash, cash equivalents and available-for-sale securities ... Free with registration - Pharma Marketletter - AccessMyLibrary.com … Enrollment of the Phase III DIRECT Trial Evaluating Daily Infergen... - Jul 11, 2005 ..."Results from independent investigator studies of daily Infergen plus ribavirin ... Response Data on Daily Infergen Regimen - - Promising ... for Company's ... Pay-Per-View - PR Newswire - HighBeam Research Event Brief of Q3 2007 Valeant Pharmaceuticals International Earnings... - Nov 1, 2007 Infergen: 1. Some products in US market have not lived up to expectations, most notably Infergen. 2. While Infergen has shown important clinical benefits in ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com 3 RIVERS PHARMA BUYS WORLDWIDE RIGHTS TO AMPHOTEC/ … - May 25, 2005 In addition to the currently marketed product indicated for the treatment of chronic hepatitis C virus (HCV) infections, three-times-a-week Infergen(R) ... $4.95 - AsiaPulse News - ECNext Press Release: InterMune Announces Clinical Data Presented at AASLD … - Nov 14, 2005 ..."Infergen(R) is currently approved for the treatment of chronic HCV infection ... The authors concluded that these data suggest that daily Infergen(R) plus ... Pay-Per-View - PR Newswire - HighBeam Research InterMune Announces Webcast of Corporate Presentation at the … - Jan 11, 2005 Leading the hepatology portfolio is the DIRECT Trial, a Phase III study of daily Infergen(R) (interferon alfacon-1) plus ribavirin, and a Phase IIb trial of ... $4.95 - PR Newswire - ECNext … obtiene derechos comerciales adicionales para Infergen de Amgen... - Sep 17, 2008 ..."La expansión de los derechos comerciales para Infergen cumplimenta la estrategia de ... Infergen, o consensus interferon, es un interferón alfa de tipo 1 ... Finanzas.com Q4 2004 InterMune Inc. Earnings Conference Call - Part 2. - Feb 7, 2005 Now a launch, as you know Tom, is expensive, and we consider Infergen still to ... We think this is the right investment for the brand, for Infergen at this ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Valeant продает маркетинговые права на Infergen в СШÐ? и Канаде - Dec 21, 2007 Ð?мериканÑ?каÑ? фармкомпаниÑ? Valeant Pharmaceuticals International объÑ?вила о продаже чаÑ?тной компании Three Rivers Pharmaceuticals маркетинговых прав на ... ФармацевтичеÑ?кий веÑ?тник By: Ivanhoe Broadcast News - Feb 8, 2007 Infergen can treat people with hepatitis C who aren't cured by the ... Infergen is an interferon that has a much higher potency than other interferons. ... News 8 Austin Orange County Business Journal Online - Nov 19, 2007 Earlier this month, Valeant said it would sell Infergen, a hepatitis C drug that it ... Back when Valeant bought Infergen, it was awaiting trial results for ... Orange County Business Journal - Orange County Business Journal Three Rivers Pharmaceuticals(R) 從Amgen Inc. ä¸ç?²å¾—æ›´å¤šå¹²å¾©æ´¥å•†æ¥ … - Sep 17, 2008 ...醫師和患者å?¯ä»¥è¨ªå•?http://www.infergen.com ç?²å?–干復津的更多處方信æ?¯ã€?安全資料以å?Š 所有與α å¹²æ“¾ç´ ç›¸é—œçš„ç¥žç¶“ç²¾ç¥žæ€§ã€?自身å…?疫性ã€?缺血性和感染性疾病的包è£?ç›’è¦ç¤ºã€‚ ... 財è?¯ç¶² InterMune Announces Presentations at the 56th Annual Meeting of the … - Nov 8, 2005 Viral Factors which Predicted Liver-Related Deaths and Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B About Infergen(R) ... Free with registration - PR Newswire - AccessMyLibrary.com InterMune, Brisbane, CA, March 28 (DDMAC).(CFSAN AND DDMAC … - May 1, 2006 DDMAC reviewed a journal advertisement with a brief summary for Infergen ... The Indications and Usage section of the FDA-approved PI for Infergen states ... $4.95 - Warning Letter Bulletin - ECNext InterMune Announces First Quarter Financial Results; - Three Phase... - Apr 28, 2005 Sales of Infergen were $7.8 million for the first quarter of 2005 compared to $4.0 ... The increase was primarily due to higher spending on Infergen-related ... $4.95 - PR Newswire - ECNext … (R), LLC ottiene ulteriori diritti commerciali per Infergen(R) da... - Sep 17, 2008 La società gode attualmente dei diritti commerciali su Infergen negli Stati Uniti e in ... Infergen, o consensus interferon, è un interferone alfa di tipo 1 ... ITNews Press Release: MIGENIX receives approval to initiate MX-3253 Phase... - Aug 11, 2005 These patients are referred ... studies of daily Infergen plus ribavirin in the ... Article: InterMune Announces Presentation of Clinical Data on Infergen . ... Pay-Per-View - PR Newswire - HighBeam Research Event Brief of Q4 2005 Valeant Pharmaceuticals International Earnings... - Feb 28, 2006 Prescriptions for Infergen have been on upward slope, increasing 85% in Jan. ... Purchase of infergen provides VRX with sales force of 50 representatives ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Edmonds v. Rees, No. 3:06-CV-P301-H (WDKy. 03/19/2008) - Mar 19, 2008 KSR doctor, Dr. Khayat, prescribed Infergen for Plaintiff and sent a Non Formulary ... He explains that Pegasys and Infergen are Interferon-based drugs. ... $2.95 - U.S. District Court, Western District... - VersusLaw InterMune Announces Fourth Quarter and Full Year 2006 Financial … - Feb 8, 2007 As a result of the December 30, 2005, divestiture of Infergen(R) and in compliance with US Generally Accepted Accounting Principals (GAAP), ... Free with registration - PR Newswire - AccessMyLibrary.com Valeant Pharaceuticals shares climb on upbeat view of hepatitis drug... - Dec 2, 2005 Launched in the United States in 1997, Infergen is a treatment for adult patients ... For the first nine months of the year, sales of Infergen increased 79 ... Pay-Per-View - AP Worldstream - HighBeam Research Business & Finance; Hepatitis drug developer sharpens focus on key … - Jan 10, 2006 ..."With the substantial cash infusion from the sale of Infergen, ... "Although Infergen has generated strong revenue growth over the past 2 years, ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Loislaw Federal District Court Opinions - EDMONDS v. REES (WDKy. 10- … - Oct 11, 2006 Therefore, Dr. Cecil had asked the jail to discontinue that treatment but suggested that the plaintiff receive Infergen every day. An October 21, 2004, ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw Article: Valeant Shares Advance on Review of Drug - Dec 2, 2005 Launched in the United States in 1997, Infergen is a treatment for adult patients ... "Why would (Valeant) pay $135 million or so for Infergen and take the ... Pay-Per-View - AP Online - HighBeam Research Article: HCV therapy during HIV coinfection.(CLINICAL CAPSULES)(Brief... - Jan 15, 2005 Article: Data on Infergen plus ribavirin in hepatitis C ... ... Article: InterMune Announces Presentation of Clinical Data on Infergen ... ... Pay-Per-View - Internal Medicine News - HighBeam Research Valeant Pharmaceuticals Reports 2007 First Quarter Results - May 1, 2007 In addition, sales of Infergen and Efudex were lower in the 2007 first quarter, ... The decrease in sales of Infergen largely reflects a decline in the ... Genetic Engineering News - Genetic Engineering News (press release) The Bellwether Report continues to track the movements made by … - Feb 6, 2006 Included in fourth quarter 2005 net income was a gain of $85.1 million, or $2.63 per share, associated with the divestiture of Infergen (interferon ... Free with registration - M2 Presswire - AccessMyLibrary.com Orange County Business Journal Online - Jan 7, 2008 The Aliso Viejo drug maker said in December that it would sell Infergen to Three Rivers ... In November, Valeant said it planned on selling Infergen, ... Orange County Business Journal - Orange County Business Journal Hep C Help - Health News Story - WFTV Orlando - Mar 20, 2007 Infergen is an interferon that has a much higher potency than other interferons. ... Infergen is not as easy to take, as it must be given once a day, ... WFtv.com Valeant Pharmaceuticals International at Citigroup Healthcare … - May 24, 2007 Infergen is the only approved treatment for refractory patients for hepatitis C. We purchased Infergen at the beginning of 2006, but sales performance since ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Press Release: Intermune Announces Issuance of Two Composition of … - Sep 7, 2005 In addition to three-times-a-week Infergen(R) (interferon alfacon-1), ... DIRECT Trial, a Phase III study of daily Infergen ... Additionally, ... ... Pay-Per-View - PR Newswire - HighBeam Research … (R), LLC erwirbt von Amgen Inc. weitere Vermarktungsrechte an Inferg... - Sep 17, 2008 Derzeit verfügt Three Rivers Pharmaceuticals über das Recht, Infergen in den Vereinigten ... "Die Ausweitung der Vermarktungsrechte für Infergen ist eine ... presseportal.de Three Rivers Pharmaceuticals(R), LLC obtient de la part d'Amgen Inc.... - Sep 17, 2008 L'élargissement des droits commerciaux d'Infergen s'inscrit dans la stratégie de Three Rivers Pharmaceuticals qui consiste à continuer à développer sa ... Caducée.net Event Brief of Q1 2006 InterMune Inc. Earnings Conference Call -... - Apr 27, 2006 2005 revenue and expense associated with Infergen, a product the Co. divested ... SG&A expense does not include expenses from Infergen that were reported as ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Green v. State, 165 P.3d 118, 42 Cal.4th 254, 64 Cal.Rptr.3d 390, 19... - Aug 23, 2007 Plaintiff received Infergen injections as a treatment for hepatitis C. A single course of treatment required injections three times a week for a one-year ... $2.95 - California Supreme Court - VersusLaw California Supreme Court Reports - GREEN v. STATE, 42 Cal.4th 254 ( … - Aug 23, 2007 Plaintiff received Infergen injections as a treatment for hepatitis C. A single course of treatment required injections three times a week for a one-year ... Pay-Per-View - California Supreme Court Reports - Loislaw Finance; Pulmonology-focused pharmaceutical company records net loss … - Nov 28, 2005 Infergen revenues for the third quarter of 2005 increased by 63% to $10.2 million from $6.2 million for the same period in 2004. ... Pay-Per-View - Biotech Business Week - Factiva, from Dow Jones Press Release: InterMune Announces Webcast of Corporate Presentation … - Sep 21, 2005 In addition to three-times-a-week Infergen(R) (interferon alfacon-1), ... DIRECT Trial, a Phase III study of daily Infergen ... Additionally, ... ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: InterMune Announces Divestiture of Amphotec. - PR … - May 24, 2005 InterMune currently markets Infergen, a bio ... President and Chief Executive Officer of InterMune. "We look forward to completing this ... ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: InterMune to Release Third Quarter Financial Results... - Oct 14, 2005 In addition to three-times-a-week Infergen(R) (interferon alfacon-1), ... DIRECT Trial, a Phase III study of daily Infergen ... Additionally, ... ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: InterMune Reaches Preliminary Settlement Agreement for... - May 9, 2005 In addition to the currently marketed product indicated for the treatment of chronic hepatitis C virus (HCV) infections, three-times-a-week Infergen(R) ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: InterMune to Release Second Quarter Financial Results ... - Jul 12, 2005 In addition to the currently marketed product indicated for the treatment of chronic hepatitis C virus (HCV) infections, three-times-a-week Infergen(R) ... Pay-Per-View - PR Newswire - HighBeam Research California Courts of Appeal Reports - GREEN v. STATE OF CALIFORNIA, … - Nov 16, 2005 At about the same time, plaintiff began a second course of Infergen injections to treat his Hepatitis C. The treatments began in April of 1999 and were ... Pay-Per-View - California Courts of Appeal Reports - Loislaw Monday's Health Winners & Losers - Nov 2, 2007 Bear Stearns downgraded the stock to underperform from peer perform on Monday, in addition to lowering price estimates and removing Infergen from revenue ... TheStreet.com - TheStreet.com (subscription) Valeant Pharma sells US and Canadian rights on hepatitis C drug - Dec 20, 2007 N) agreed to sell its US and Canadian rights on hepatitis C drug Infergen to privately held Three Rivers Pharmaceuticals, which will also acquire the ... Reuters Siaran Media Eksklusif - Sep 17, 2008 Three Rivers Pharmaceuticals Akan Memperoleh Hak Komersil Untuk Infergen Dalam Semua Pasaran Kecuali Jepun. Sebagai tambahan, Three Rivers Pharmaceuticals ... Bernama - Bernama Valeant Pharmaceuticals Reports Second Quarter 2007 Results.( … - Aug 2, 2007 Sales of Infergen declined in the 2007 second quarter compared to the same period last year, ... Infergen is a registered trademark of Amgen, Inc., ... Free with registration - Business Wire - AccessMyLibrary.com Valeant Pharmaceuticals International at Bear Stearns 19th Annual … - Sep 12, 2006 Infergen is the only approved treatment for refractory patients with ... We are conducting the DIRECT trial to evaluate the daily use of Infergen with ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com InterMune Announces Webcast of Corporate Presentation at the UBS … - Sep 21, 2005 In addition to three-times-a-week Infergen(R) (interferon alfacon-1), a currently marketed product indicated for the treatment of chronic hepatitis C virus ... RedOrbit InterMune to Release Second Quarter Financial Results on July 28 - Jul 12, 2005 In addition to the currently marketed product indicated for the treatment of chronic hepatitis C virus (HCV) infections, three-times-a-week Infergen(R) ... RedOrbit |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |